Tian Mengxiang, Dong Bingzhi, Li Weiqi, Wang Liying, Yu Hong
Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.
Provincial Key Laboratory of Precise Diagnosis and Treatment of Abdominal Infection, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Pharmaceutics. 2024 Oct 18;16(10):1339. doi: 10.3390/pharmaceutics16101339.
The growing global prevalence of chronic diseases has highlighted the limitations of conventional drug delivery methods, which often suffer from non-specific distribution, systemic toxicity, and poor bioavailability. Microscale and nanoscale materials have emerged as innovative solutions, offering enhanced targeting, controlled release, and the convergence of therapeutic and diagnostic functions, referred to as theranostics. This review explores the design principles, mechanisms of action, and clinical applications of various novel micro- and nanomaterials in diseases such as cancer, cardiovascular disorders, and infectious diseases. These materials enable real-time monitoring of therapeutic responses and facilitate precision medicine approaches. Additionally, this paper addresses the significant challenges hindering clinical translation, including biocompatibility, potential toxicity, and regulatory issues. Ongoing clinical trials demonstrate the potential of nanomaterials in theranostic applications, but further research is needed to overcome the barriers to widespread clinical adoption. This work aims to contribute to the acceleration of integrating nanomedicine into clinical practice, ultimately enhancing the efficacy and safety of therapeutic interventions.
全球慢性病患病率的不断上升凸显了传统药物递送方法的局限性,这些方法常常存在非特异性分布、全身毒性和生物利用度差等问题。微米级和纳米级材料已成为创新解决方案,具有增强的靶向性、控释功能以及治疗与诊断功能的融合,即所谓的诊疗一体化。本综述探讨了各种新型微米和纳米材料在癌症、心血管疾病和传染病等疾病中的设计原则、作用机制及临床应用。这些材料能够实时监测治疗反应,并促进精准医学方法的应用。此外,本文还讨论了阻碍临床转化的重大挑战,包括生物相容性、潜在毒性和监管问题。正在进行的临床试验证明了纳米材料在诊疗一体化应用中的潜力,但仍需进一步研究以克服广泛临床应用的障碍。这项工作旨在推动纳米医学融入临床实践的加速进程,最终提高治疗干预的疗效和安全性。